It's common knowledge that diabetics receive their insulin through injections or pumps. However, many people don't know of a new option. Inhalable insulin is available to adults, and a local study could soon make it available to kids.
Share this article
Share this article
ABBOTT PARK, Ill., Jan. 27, 2021 /PRNewswire/ Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2020, and issued its financial outlook for 2021.
Fourth-quarter sales of $10.7 billion increased 28.7 percent on a reported basis and 28.4 percent on an organic basis, which excludes the impact of foreign exchange.
Fourth-quarter GAAP diluted EPS was $1.20 and adjusted diluted EPS, which excludes specified items, was $1.45, reflecting 52.6 percent growth versus the prior year.
1
Full-year 2020 GAAP diluted EPS from continuing operations was $2.49 and adjusted diluted EPS from continuing operations was $3.65, at the upper-end of guidance range issued in January 2020.